VI. Period of Agreement

The agreement becomes effective upon signature of both parties and will continue without expiration. It may be modified by mutual consent or terminated by either party upon 120 days written notice.

APPROVED AND ACCEPTED FOR THE NATIONAL LIBRARY OF MEDICINE

By _____

Betsy Humphreys
Deputy Director
National Library of Medicine

Date 6/23/2005

APPROVED AND ACCEPTED FOR THE CENTER FOR DRUG EVALUATION AND RESEARCH

By _____

Janet Woodcock, MD (Acting)
Deputy Commissioner for Operations
Office of the Commissioner

Date 7/08/05

[FR Doc. 05–19340 Filed 9–27–05; 8:45 am]

BILLING CODE 4160–01–C

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration

Advisory Committee on Heritable Disorders and Genetic Diseases in Newborns and Children; Notice of Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), notice is hereby given of the following meeting:

Name: Advisory Committee on Heritable Disorders and Genetic Diseases in Newborns and Children (ACHDGDNC).

Dates and Times: October 20, 2005, 9 a.m. to 5 p.m.; October 21, 2005, 9 a.m. to 3 p.m.

Place: Ronald Reagan Building and International Trade Center, 1300 Pennsylvania Avenue, NW., Washington, DC 20004.

Status: The meeting will be open to the public with attendance limited to space availability.

Purpose: The Advisory Committee provides advice and recommendations concerning the grants and projects authorized under the Heritable Disorders Program and technical information to develop policies and priorities for this program. The Heritable Disorders Program was established to enhance the ability of State and local health agencies to provide for newborn and child screening, counseling and health care services for newborns and children having or at risk for heritable disorders. The Committee was established specifically to advise and guide the Secretary regarding the most appropriate application of universal newborn screening tests, technologies, policies, guidelines and programs for effectively reducing morbidity and mortality in newborns and children having or at risk for heritable disorders.

Agenda: The first day will be devoted to presentations on and a discussion of the decision-making methodology of the Committee and an update of the current status of State specific issues. The second day will include meetings and reports from the Committee's subcommittees on laboratory standards and procedures, follow-up and treatment and education and training.

Proposed agenda items are subject to change.

Public Comments: Time will be provided each day for public comment. Individuals who wish to provide public comment or who plan to attend the meeting and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the ACHDGDNC Executive Secretary, Michele A. Lloyd-Puryear, M.D., Ph.D. (contact information provided below).

Contact Person: Anyone interested in obtaining a roster of members or other relevant information should write or contact Michele A. Lloyd-Puryear, M.D., Ph.D., Maternal and Child Health Bureau, Health Resources and Services Administration, Room 18A–19, Parklawn Building, 5600 Fishers Lane, Rockville, Maryland 20857, Telephone (301) 443–1080. Information on the Advisory Committee is available at *http://mchb.hrsa.gov/programs/genetics/committee*.

Dated: September 20, 2005.

Tina M. Cheatham,

Director, Division of Policy Review and Coordination.

[FR Doc. 05–19295 Filed 9–27–05; 8:45 am]

BILLING CODE 4165–15–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Office of the Director, National Institutes of Health; Notice of Meeting

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the Director's Council of Public Representatives.

The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

Name of Committee: Director's Council of Public Representatives.

Date: October 25, 2005.

Time: 8:30 a.m. to 3 p.m.

Agenda: Among the topics proposed for discussion are: (1) NIH Director's update; (2) COPR workgroup reports; (3) public perspective on the NIH Roadmap; (4) updates on the NIH Re-authorization and the Office of Portfolio Analysis and Strategic Initiatives; (5) NIH response to COPR's Public Trust Report; and (6) discussion and public comment.

Place: National Institutes of Health, Building 31, Conference Room 6, 9000 Rockville Pike, Bethesda, MD 20892.

Contact Person: Jennifer E. Gorman Vetter, NIH Public Liaison/COPR Coordinator, Office of Communications and Public Liaison, Office of the Director, National Institutes of Health, 9000 Rockville Pike, Building 1, Room 344, Bethesda, MD 20892. (301) 435–4448. *gormanj@od.nih.gov.*

Any member of the public interested in presenting oral comments to the committee may notify the Contact Person listed on this